Management of pregnancy in women with antithrombin III congenital defect: report of four cases.
Four pregnant women with antithrombin III congenital deficiency underwent thrombosis prophylaxis including oral anticoagulants administered from the 16-18th week to the 36-37th week of pregnancy, subcutaneous heparin before the 16-18th week and after the 36-37th week, and a single infusion of AT III concentrate in the peripartum period in order to obtain a minimal level of 0.8 U/ml of AT III functional activity. The level of circulating AT III after the concentrate infusion needs to be evaluated by functional methods, because of a consistent amount in the concentrates of inactive AT III immunoreactive material. No thrombotic or haemorrhagic complication occurred after starting prophylaxis in any woman either in any newborn.
De Stefano
V
V
Istituto di Semeiotica Medica, Università Cattolica, Roma, Italy.
Leone
G
G
De Carolis
S
S
Ferrelli
R
R
Di Donfrancesco
A
A
Moneta
E
E
Bizzi
B
B
D000284:Administration, Oral; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage; D000990:Antithrombin III / Q000378:metabolism / Q000627:therapeutic use; D020152:Antithrombin III Deficiency; D015951:Factor Xa; D005260:Female; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007231:Infant, Newborn; D007279:Injections, Subcutaneous; D008297:Male; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000188:drug therapy*; D015842:Serine Proteinase Inhibitors; D013923:Thromboembolism / Q000517:prevention & control
D000925:Anticoagulants; D015842:Serine Proteinase Inhibitors; D000990:Antithrombin III; D006493:Heparin; D015951:Factor Xa